Vaccine Monitoring Platform research agenda
The Vaccine Monitoring Platform (VMP) is a collaboration between EMA and ECDC for the timely generation of independent real-world evidence (RWE) on the safety and effectiveness of vaccines in use in EU/EEA immunisation programs.
Invitation to participate in the second public survey to inform the global research agenda on Public Health and Social Measures
WHO welcomes stakeholders from sectors such as health, education, transportation, agriculture, finance, social services to complete a public survey to identify priorities for a global research agenda on Public Health and Social Measures (PHSM).
A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Benefits of ensitrelvir in Covid-19 and long Covid highlighted in two studies
The benefits of ensitrelvir use in patients with symptoms of long Covid and as a second-line treatment option for those hospitalised with Covid-19.
Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases
Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan
CD8+ T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear.
Joint EMA-ECDC press briefing on current state of respiratory diseases and treatments in the EU/EEA
As autumn season approaches the EMA and ECDC held a press briefing to provide latest information on respiratory diseases as well as vaccines and treatments available
WHO welcomes historic commitment by world leaders for greater collaboration, governance and investment to prevent, prepare for and respond to future pandemics
“The first-ever head of state summit on pandemic prevention, preparedness and response is a historic milestone in the urgent drive to make all people of the world safer, and better protected from the devastating impacts of pandemics,” said Dr Tedros
CYP19A1 mediates severe SARS-CoV-2 disease outcome in males
International scientific community gathers in Valencia for the 9th ESWI Conference on Influenza, COVID-19, and RSV
Since it was established 30 years ago, the European Scientific Working Group on Influenza and other Acute Respiratory Viruses (ESWI) is hosting the 9TH ESWI Influenza Conference
SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters
Two doses of COVID-19 mRNA vaccines in the primary series and a booster dose induce a strong antibody response, however, this response can be weak in people older than 80 years.
